Internal Medicine, Nephrology · Staten Island, NY
NPI
1568554806
Since 2006
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
1550 Richmond Ave, Suite 205
Staten Island, NY, 10314
Phone (718) 982-7800
Groups this clinician bills Medicare through
Medicare paid, 2024
$214K
8,665 services
Medicare patients, 2024
669
Average age 75
Drug cost, 2024
$651K
4,712 prescriptions
Company payments, 2025
$116
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Matthew Palombini was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 6,850 times for 12 patients. In total Matthew Palombini billed 8,665 services in 27 codes, and Medicare paid $214K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-07-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 6,850 | 12 | $2.27 | $16K |
| 99213 Office E&M - Established | Office | 623 | 378 | $51.50 | $32K |
| 99214 Office E&M - Established | Office | 384 | 234 | $68.33 | $26K |
| 90960 ESRD Related Services (not dialysis) | Office | 254 | 36 | $283.19 | $72K |
| 90966 ESRD Related Services (not dialysis) | Office | 98 | 20 | $237.84 | $23K |
| 99232 Hospital E&M - Subsequent | Facility | 60 | 44 | $65.11 | $3,907 |
| 99204 Office E&M - New | Office | 58 | 58 | $140.99 | $8,177 |
| 90961 ESRD Related Services (not dialysis) | Office | 58 | 24 | $240.82 | $14K |
| 99233 Hospital E&M - Subsequent | Facility | 54 | 41 | $96.05 | $5,187 |
| 96372 Injection Administration | Office | 35 | 12 | $11.79 | $413 |
| 99222 Hospital E&M - Initial | Facility | 35 | 35 | $108.57 | $3,800 |
| 81002 Clinical Chemistry | Office | 34 | 34 | $3.41 | $116 |
| 90935 Hemodialysis | Facility | 30 | 25 | $55.99 | $1,680 |
| 99441 Telephone Services | Office | 24 | 18 | $29.98 | $720 |
| 99215 Office E&M - Established | Office | 17 | 16 | $74.32 | $1,263 |
By year: 2022 $244K for 7,961 services; 2023 $251K for 13,528 services; 2024 $214K for 8,665 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81002 Clinical Chemistry | 34 | 34 | $3.41 | $116 |
Medicare prescription drug claims, 2024
In 2024, the drug Matthew Palombini prescribed most often to Medicare patients was Nifedipine Er (Nifedipine), with 263 prescriptions and refills. In total Matthew Palombini wrote 4,712 Medicare prescriptions that cost $651K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Nifedipine Er Nifedipine | 263 | 705 | 79 | $12K |
| Chlorthalidone Generic | 224 | 636 | 62 | $5,598 |
| Paricalcitol Generic | 218 | 588 | 64 | $31K |
| Calcitriol Generic | 189 | 500 | 60 | $2,931 |
| Atorvastatin Calcium Generic | 189 | 514 | 58 | $1,754 |
| Amlodipine Besylate Generic | 163 | 473 | 59 | $1,091 |
| Olmesartan Medoxomil Generic | 151 | 407 | 45 | $2,750 |
| Rosuvastatin Calcium Generic | 131 | 358 | 36 | $1,524 |
| Losartan Potassium Generic | 115 | 314 | 47 | $937 |
| Candesartan Cilexetil Generic | 114 | 301 | 29 | $5,462 |
| Labetalol Hcl Generic | 108 | 300 | 35 | $4,202 |
| Kerendia Finerenone | 107 | 176 | 20 | $112K |
| Doxazosin Mesylate Generic | 105 | 295 | 32 | $2,692 |
| Farxiga Dapagliflozin Propanediol | 99 | 197 | 26 | $106K |
| Pentoxifylline Generic | 94 | 244 | 25 | $3,983 |
Brand drugs: - claims; generic drugs: 4,181 claims; opioid claims: 30.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Matthew Palombini $116 ($116 in general payments such as food, travel and fees) from 3 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $70.26.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.